logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Gets Complete Response Letter From FDA On Lemtrada Application

Genzyme, a Sanofi company (SNY,SNYNF.PK), said it has received a Complete Response Letter from the U.S. Food and Drug Administration or FDA for its supplemental Biologics License Application seeking approval of Lemtrada or alemtuzumab for the treatment of relapsing forms of multiple sclerosis. Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells.

A Complete Response Letter informs companies that an application is not yet ready for approval. FDA has taken the position that Genzyme has not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects. Genzyme understands that the conclusion is related to the design of the completed Phase 3 active comparator studies of Lemtrada in relapsing-remitting MS patients. Moreover, FDA has taken the position that one or more additional active comparator trials of different design and execution are needed prior to the Lemtrada approval.

Genzyme strongly disagrees with the FDA's conclusions and intends to appeal the agency's decision.

Lemtrada is approved in the European Union, Canada, and Australia, and additional marketing applications for Lemtrada are under review by regulatory agencies worldwide. Sanofi does not expect that the CVR milestone of U.S. approval of Lemtrada by March 31, 2014 would be met.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT